Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Akero Therapeutics Inc
(NQ:
AKRO
)
30.83
+0.13 (+0.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Akero Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
October 21, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
September 30, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
September 20, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
September 12, 2024
Via
Benzinga
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
September 09, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
August 26, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q2 2024
August 09, 2024
AKRO stock results show that Akero Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 09, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
July 15, 2024
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's Q2 FY24 earnings report on August 8 will include a pre-tax IPR&D charge of...
Via
Benzinga
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
June 28, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
June 25, 2024
From
The Schall Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)
June 24, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO
June 24, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
June 24, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
June 24, 2024
From
The Schall Law Firm
Via
Business Wire
AKERO THERAPEUTICS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
June 21, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
June 21, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
June 21, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
June 21, 2024
From
Schall Law
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO
June 20, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
June 19, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
June 18, 2024
From
Schall Law
Via
GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
June 17, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
June 13, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
June 12, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
June 11, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm
June 11, 2024
From
Schall Law
Via
GlobeNewswire
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
June 11, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
June 10, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.